These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12081594)

  • 1. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
    Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
    Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
    Struijk GH; Minnee RC; Koch SD; Zwinderman AH; van Donselaar-van der Pant KA; Idu MM; ten Berge IJ; Bemelman FJ
    Kidney Int; 2010 Nov; 78(9):934-40. PubMed ID: 20703211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment.
    Hutchinson P; Jose M; Atkins RC; Holdsworth SR
    Transpl Immunol; 2004; 13(1):55-61. PubMed ID: 15203129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response.
    Weimer R; Deisz S; Dietrich H; Renner F; Bödeker RH; Daniel V; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
    Transpl Int; 2011 Jun; 24(6):596-609. PubMed ID: 21401729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols.
    Legris T; Picard C; Moal V; Burtey S; Loundou A; Purgus R; Dussol B; Berland Y; Vacher-Coponat H
    Ann Transplant; 2013 Nov; 18():622-34. PubMed ID: 24231646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
    Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
    J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil.
    Millán O; Brunet M; Campistol JM; Faura A; Rojo I; Vidal E; Jiménez O; Vives J; Oppenheimer F; Martorell J
    Clin Chem; 2003 Nov; 49(11):1891-9. PubMed ID: 14578321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
    Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
    Libetta C; Sepe V; Zucchi M; Portalupi V; Meloni F; Rampino T; Dal Canton A
    Kidney Int; 2007 Jul; 72(1):114-20. PubMed ID: 17410097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
    Bunnapradist S; Daswani A; Takemoto SK
    Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts.
    Shimizu H; Takahashi M; Takeda S; Inoue S; Fujishiro J; Hakamata Y; Kaneko T; Murakami T; Takeyoshi I; Morishita Y; Kobayashi E
    Transpl Immunol; 2004 Nov; 13(3):219-27. PubMed ID: 15381205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrocyte sodium lithium countertransport in renal transplant recipients with mycophenolate mofetil and low-dose cyclosporine.
    Vareesangthip K; Hanlakorn P; Suwannaton L; Larpkitkachorn R; Chuawattana D; Pidetcha P; Ong-Aj-Yooth L
    Transplant Proc; 2004 Dec; 36(10):3032-5. PubMed ID: 15686688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose versus high-dose cyclosporine induction protocols in renal transplantation.
    Ghafari A; Makhdoomi K; Ahmadpour P; Afshari AT; Fallah MM; Rad PS
    Transplant Proc; 2007 May; 39(4):1219-22. PubMed ID: 17524937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells.
    Raab M; Daxecker H; Karimi A; Markovic S; Cichna M; Markl P; Müller MM
    Clin Chim Acta; 2001 Aug; 310(1):89-98. PubMed ID: 11485760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell reactivity during tapering of immunosuppression to low-dose monotherapy prednisolone in HLA-identical living-related renal transplant recipients.
    Gerrits JH; van de Wetering J; Weimar W; van Besouw NM
    Transplantation; 2009 Mar; 87(6):907-14. PubMed ID: 19300195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.